Volatile fingerprints of cancer specific genetic mutations

被引:92
作者
Peled, Nir [1 ,2 ]
Barash, Orna [3 ,4 ]
Tisch, Ulrike [3 ,4 ]
Ionescu, Radu [3 ,4 ,5 ]
Broza, Yoav Y. [3 ,4 ]
Ilouze, Maya [1 ]
Mattei, Jane [2 ]
Bunn, Paul A., Jr. [2 ]
Hirsch, Fred R. [2 ]
Haick, Hossam [3 ,4 ]
机构
[1] Sheba Med Ctr, Thorac Canc Res & Detect Ctr, Tel Aviv, Israel
[2] Univ Colorado Canc Ctr, Aurora, CO USA
[3] Technion Israel Inst Technol, Dept Chem Engn, IL-3200003 Haifa, Israel
[4] Technion Israel Inst Technol, Russell Berrie Nanotechnol Inst, IL-3200003 Haifa, Israel
[5] Univ Rovira & Virgili, Dept Elect Elect & Automat Engn, E-43007 Tarragona, Spain
关键词
Lung cancer; Genetic; Mutation; Volatile organic compound; Sensor; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; ORGANIC-COMPOUNDS; EXHALED BREATH; BIOMARKERS; EGFR; EXPRESSION; PREDICTION; SURVIVAL;
D O I
10.1016/j.nano.2013.01.008
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
We report on a new concept for profiling genetic mutations of (lung) cancer cells, based on the detection of patterns of volatile organic compounds (VOCs) emitted from cell membranes, using an array of nanomaterial-based sensors. In this in-vitro pilot study we have derived a volatile fingerprint assay for representative genetic mutations in cancer cells that are known to be associated with targeted cancer therapy. Five VOCs were associated with the studied oncogenes, using complementary chemical analysis, and were discussed in terms of possible metabolic pathways. The reported approach could lead to the development of novel methods for guiding treatments, so that patients could benefit from safer, more timely and effective interventions that improve survival and quality of life while avoiding unnecessary invasive procedures. Studying clinical samples (tissue/blood/breath) will be required as next step in order to determine whether this cell-line study can be translated into a clinically useful tool. From the Clinical Editor: In this novel study, a new concept for profiling genetic mutations of (lung) cancer cells is described, based on the detection of patterns of volatile organic compounds emitted from cell membranes, using an array of nano-gold based sensors. (c) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:758 / 766
页数:9
相关论文
共 44 条
[1]   The scent fingerprint of hepatocarcinoma: in-vitro metastasis prediction with volatile organic compounds (VOCs) [J].
Amal, Haitham ;
Ding, Lu ;
Liu, Bin-bin ;
Tisch, Ulrike ;
Xu, Zhen-qin ;
Shi, Da-you ;
Zhao, Yan ;
Chen, Jie ;
Sun, Rui-xia ;
Liu, Hu ;
Ye, Sheng-Long ;
Tang, Zhao-you ;
Haick, Hossam .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2012, 7 :4135-4146
[2]   Breath Analysis: The Approach Towards Clinical Applications [J].
Amann, Anton ;
Spanel, Patrik ;
Smith, David .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2007, 7 (02) :115-129
[3]  
Amann A, 2011, EXPERT REV MOL DIAGN, V11, P207, DOI [10.1586/ERM.10.112, 10.1586/erm.10.112]
[4]   Noninvasive detection of lung cancer by analysis of exhaled breath [J].
Bajtarevic, Amel ;
Ager, Clemens ;
Pienz, Martin ;
Klieber, Martin ;
Schwarz, Konrad ;
Ligor, Magdalena ;
Ligor, Tomasz ;
Filipiak, Wojciech ;
Denz, Hubert ;
Fiegl, Michael ;
Hilbe, Wolfgang ;
Weiss, Wolfgang ;
Lukas, Peter ;
Jamnig, Herbert ;
Hackl, Martin ;
Haidenberger, Alfred ;
Buszewski, Boguslaw ;
Miekisch, Wolfram ;
Schubert, Jochen ;
Amann, Anton .
BMC CANCER, 2009, 9 :348
[5]   Classification of lung cancer histology by gold nanoparticle sensors [J].
Barash, Orna ;
Peled, Nir ;
Tisch, Ulrike ;
Bunn, Paul A., Jr. ;
Hirsch, Fred R. ;
Haick, Hossam .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2012, 8 (05) :580-589
[6]   Sniffing the Unique "Odor Print" of Non-Small-Cell Lung Cancer with Gold Nanoparticles [J].
Barash, Orna ;
Peled, Nir ;
Hirsch, Fred R. ;
Haick, Hossam .
SMALL, 2009, 5 (22) :2618-2624
[7]   Changes in the Content of Protein and Lipid Oxidative Modification Products in Tumor Tissue at Different Stages of Lung Cancer [J].
Belonogov, R. N. ;
Titova, N. M. ;
Lapeshin, P. V. ;
Ivanova, Yu. R. ;
Shevtsova, A. O. ;
Pokrovskii, A. A. .
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2009, 147 (05) :630-631
[8]  
Brereton RG, 1990, CHEMOMETRICS APPL MA
[9]   EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) [J].
Cappuzzo, Federico ;
Ligorio, Claudio ;
Toschi, Luca ;
Rossi, Elisa ;
Trisolini, Rocco ;
Paioli, Daniela ;
Magrini, Elisabetta ;
Finocchiaro, Giovanna ;
Bartolini, Stefania ;
Cancellieri, Alessandra ;
Hirsch, Fred R. ;
Crino, Lucio ;
Varella-Garcia, Marileila .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (05) :423-429
[10]   New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer [J].
Doebele, Robert C. ;
Oton, Ana B. ;
Peled, Nir ;
Camidge, D. Ross ;
Bunn, Paul A., Jr. .
LUNG CANCER, 2010, 69 (01) :1-12